Dignify Therapeutics
PrivateLast Round
Seed Round
Sep 15, 2026
Total Funding Raised
$9.95M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Dignify Therapeutics operates in Healthcare & Life Sciences and is based in North Carolina. Its latest recorded funding round was a Grant round in September 2024.
Dignify Therapeutics is a biopharmaceutical company that develops novel drug and medical device therapies to restore voluntary control of bladder and bowel function for individuals with neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dignify Therapeutics Comparables
Compare Dignify Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cyllene Therapeutics | 74% | |
| AbbVie | 69% | |
| Dentsply Sirona Inc. | 61% |
For institutional investors. Book with your work email.
Dignify Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Sep 15, 2026 | ||||
| Grant | Sep 19, 2024 | ||||
| Grant | Feb 27, 2023 | ||||
| Grant | Sep 28, 2020 | ||||
| Seed | Feb 10, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Dignify Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Seed |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| National Institute on Aging | Grant |
| Eshelman Ventures | Seed |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| North Carolina Biotechnology Center | Debt |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2026
$800K raised in Seed Round.
- Jun 19, 2026
Monthly visitors grew 95% MoM, from 1.1K to 2.2K.
For institutional investors. Book with your work email.
Dignify Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Dignify Therapeutics's valuation, stock price, and market status.
Is Dignify Therapeutics a public or private company?
Dignify Therapeutics is a private company.
What is the current stock price of Dignify Therapeutics?
Dignify Therapeutics is a private company, so its shares have no public market price. Caplight tracks Dignify Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dignify Therapeutics worth (valuation)?
Valuation information for Dignify Therapeutics is not publicly available.
Can I buy Dignify Therapeutics stock?
Dignify Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dignify Therapeutics's last funding round?
Dignify Therapeutics's most recent funding round was Seed Round on September 15, 2026.
Who are the main investors in Dignify Therapeutics?
Key investors in Dignify Therapeutics include RA Capital Management, National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging, Eshelman Ventures, National Institute of Diabetes and Digestive and Kidney Diseases.
Will Dignify Therapeutics IPO soon?
No public IPO plans have been announced for Dignify Therapeutics.
How can I track Dignify Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Dignify Therapeutics's shares on secondary markets.